In the prospective OGIPRO trial (KEK-ZH 2021-D0051), patients with HER2-positive breast cancer reported well-being and symptoms via the Medidux ePRO platform alongside weekly EQ-5D-5L assessments. This evidence concerns the gene ERBB2 and breast cancer.